SRR1465917
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.568
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.501
- OXIDATIVE_PHOSPHORYLATION+0.481
- HYPOXIA+0.409
- CHOLESTEROL_HOMEOSTASIS+0.385
- UV_RESPONSE_UP+0.377
- MYOGENESIS+0.359
- UNFOLDED_PROTEIN_RESPONSE+0.299
- ESTROGEN_RESPONSE_EARLY+0.293
- ADIPOGENESIS+0.289
Top 10 suppressed
- E2F_TARGETS-0.378
- G2M_CHECKPOINT-0.369
- PROTEIN_SECRETION-0.328
- INTERFERON_ALPHA_RESPONSE-0.244
- MITOTIC_SPINDLE-0.203
- ALLOGRAFT_REJECTION-0.156
- INTERFERON_GAMMA_RESPONSE-0.089
- UV_RESPONSE_DN-0.047
- BILE_ACID_METABOLISM-0.020
- DNA_REPAIR-0.015
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1081741 | GTEX | — | 0.860 |
| 2 | MNG610 | — | — | 0.821 |
| 3 | R170 | — | — | 0.818 |
| 4 | SRR1488349 | GTEX | — | 0.811 |
| 5 | MNG413 | — | — | 0.806 |
| 6 | SRR1314163 | GTEX | — | 0.803 |
| 7 | BS_8RHPJ740 | Ependymoma NOS | — | 0.800 |
| 8 | SRR1374414 | GTEX | — | 0.796 |
| 9 | TCGA-AC-A5EH-01A-11R-A28M-07 | — | C | 0.793 |
| 10 | BS_FYRDYBMZ | high-grade glioma | — | 0.792 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.568 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.501 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.481 | Remibrutinib | — uncovered |
| HYPOXIA | 0.409 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.385 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.377 | Idelalisib | — uncovered |
| MYOGENESIS | 0.359 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.299 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.293 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.289 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.282 | Inavolisib | — uncovered |
| APOPTOSIS | 0.281 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.258 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.253 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.249 | Cobimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.248 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.246 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.216 | Idelalisib | — uncovered |
| COAGULATION | 0.212 | Binimetinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.208 | Inavolisib | — uncovered |